S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
S&P 500   4,140.06 (-0.12%)
DOW   32,832.54 (+0.09%)
QQQ   320.71 (-0.32%)
AAPL   164.87 (-0.29%)
MSFT   280.32 (-0.92%)
META   170.25 (+1.88%)
GOOGL   117.30 (-0.14%)
AMZN   139.41 (-0.99%)
TSLA   871.27 (+0.78%)
NVDA   177.93 (-6.30%)
NIO   20.17 (-0.25%)
BABA   90.84 (-1.86%)
AMD   100.07 (-2.19%)
MU   61.45 (-1.62%)
T   18.00 (-1.91%)
CGC   3.28 (+21.48%)
GE   75.18 (+1.10%)
F   15.78 (+3.14%)
DIS   109.11 (+2.33%)
AMC   23.96 (+8.03%)
PYPL   96.26 (+0.99%)
PFE   49.57 (+0.61%)
NFLX   233.49 (+2.96%)
NASDAQ:OVID

Ovid Therapeutics - OVID Stock Forecast, Price & News

$2.20
0.00 (0.00%)
(As of 08/8/2022 05:24 PM ET)
Add
Compare
Today's Range
$2.17
$2.22
50-Day Range
$1.69
$2.22
52-Week Range
$1.65
$4.20
Volume
31,153 shs
Average Volume
179,453 shs
Market Capitalization
$154.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.40

Ovid Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
10.1% Upside
$2.40 Price Target
Short Interest
Healthy
0.65% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.98) to ($1.03) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

1066th out of 1,293 stocks

Pharmaceutical Preparations Industry

507th out of 619 stocks

OVID stock logo

About Ovid Therapeutics (NASDAQ:OVID) Stock

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Wall Street Analyst Weigh In

Separately, Citigroup decreased their target price on Ovid Therapeutics to $2.40 and set a "neutral" rating for the company in a research note on Friday, May 20th.

Ovid Therapeutics Stock Performance

Ovid Therapeutics stock opened at $2.20 on Monday. Ovid Therapeutics has a 12 month low of $1.65 and a 12 month high of $4.20. The company has a debt-to-equity ratio of 0.10, a quick ratio of 16.63 and a current ratio of 16.63. The business has a 50 day simple moving average of $1.99 and a 200-day simple moving average of $2.61.

Ovid Therapeutics (NASDAQ:OVID - Get Rating) last released its quarterly earnings results on Tuesday, May 10th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of $1.17 by ($1.40). The firm had revenue of $1.45 million during the quarter. Equities research analysts anticipate that Ovid Therapeutics will post -0.98 EPS for the current year.

Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Stock News Headlines

REAL,COMM and OVID among after hour movers
Ovid Therapeutics: Q1 Earnings Insights
Ovid Therapeutics GAAP EPS of -$0.38 misses by $0.22
Ovid Therapeutics Inc. Common Stock (OVID)
Xenon draws buyout speculation after Zogenix deal
See More Headlines
Receive OVID Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ovid Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OVID Company Calendar

Last Earnings
5/10/2022
Today
8/08/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OVID
Fax
N/A
Employees
57
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.40
High Stock Price Forecast
$2.40
Low Stock Price Forecast
$2.40
Forecasted Upside/Downside
+9.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$122.83 million
Pretax Margin
-4,733.77%

Debt

Sales & Book Value

Annual Sales
$208.38 million
Cash Flow
$1.80 per share
Book Value
$2.64 per share

Miscellaneous

Free Float
62,882,000
Market Cap
$154.92 million
Optionable
Not Optionable
Beta
1.24

Key Executives

  • Dr. Jeremy Max Levin Ba Zoology (Age 69)
    Dphil, Mb Bchir, Pres, CEO & Chairman
    Comp: $847.07k
  • Mr. Jeffrey A. Rona (Age 54)
    Principal Financial Officer, Principal Accounting Officer & Chief Bus. and Financial Officer
    Comp: $613.18k
  • Mr. Thomas Michael Perone J.D. (Age 57)
    M.B.A., Gen. Counsel, Chief Compliance Officer & Corp. Sec.
    Comp: $632.11k
  • Dr. Matthew J. During DSc (Age 65)
    FACP, FRACP, M.D., Ph.D., Founder & Member of Scientific Advisory Board
  • Mr. Jason Tardio M.B.A. (Age 45)
    Chief Operating Officer
  • Ms. Lora Pike
    Sr. Director of Investor Relations & PR
  • Ms. Suzanne K. Wakamoto SHRM-SCP
    SPHR, Sr. VP of HR
  • Dr. Dirk Haasner (Age 57)
    Sr. VP of Global Manufacturing & CMC QA
  • Dr. Claude Nicaise M.D. (Age 69)
    Head of R&D
  • Mr. Luke Rosen
    Sr. VP of Accelerated Devel. & Community Engagement













OVID Stock - Frequently Asked Questions

Should I buy or sell Ovid Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OVID shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OVID, but not buy additional shares or sell existing shares.
View OVID analyst ratings
or view top-rated stocks.

What is Ovid Therapeutics' stock price forecast for 2022?

2 analysts have issued 1-year price targets for Ovid Therapeutics' shares. Their OVID stock forecasts range from $2.40 to $2.40. On average, they predict the company's stock price to reach $2.40 in the next year. This suggests a possible upside of 8.6% from the stock's current price.
View analysts price targets for OVID
or view top-rated stocks among Wall Street analysts.

How has Ovid Therapeutics' stock price performed in 2022?

Ovid Therapeutics' stock was trading at $3.21 at the beginning of 2022. Since then, OVID stock has decreased by 31.2% and is now trading at $2.21.
View the best growth stocks for 2022 here
.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our OVID earnings forecast
.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc. (NASDAQ:OVID) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.17 by $1.40. The business earned $1.45 million during the quarter.

What other stocks do shareholders of Ovid Therapeutics own?

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (0.38%), Walker Asset Management LLC (0.06%), Walker Asset Management LLC (0.06%), Connor Clark & Lunn Investment Management Ltd. (0.05%) and Assenagon Asset Management S.A. (0.04%). Insiders that own company stock include Amit Rakhit, Jeremy M Levin and Pharmaceutical Co Ltd Takeda.
View institutional ownership trends
.

How do I buy shares of Ovid Therapeutics?

Shares of OVID stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $2.21.

How much money does Ovid Therapeutics make?

Ovid Therapeutics (NASDAQ:OVID) has a market capitalization of $155.62 million and generates $208.38 million in revenue each year. The company earns $122.83 million in net income (profit) each year or ($1.01) on an earnings per share basis.

How many employees does Ovid Therapeutics have?

Ovid Therapeutics employs 57 workers across the globe.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The official website for the company is www.ovidrx.com. The company can be reached via phone at (646) 661-7661 or via email at investors@ovidrx.com.

This page (NASDAQ:OVID) was last updated on 8/8/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.